Edwards Lifesciences' TMTT and TAVR growth, strong clinical evidence and solid balance sheet support expansion, but tariffs and currency headwinds threaten margins.

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced that the U.S. Food and Drug Administration (FDA) has approved its PASCAL Precision system for tricuspid valve repair. The system is indicated for improving quality of life and functional status in patients with symptomatic severe tricuspid regurgitation (TR) despite optimal medical therapy who are deemed at intermediate or greater risk for surgery and deemed appropriate for transcatheter edge-to-edge tr.

On October 21, 2026, we delve into the DCF analysis for Edwards Lifesciences Corp (EW), a company that has shown a 17.3% increase in price over the past year bu

Birch Hill Investment Advisors LLC lowered its stake in Edwards Lifesciences Corporation (NYSE: EW) by 1.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 723,022 shares of the medical research company's stock after selling 12,355 shares during the quarter. Edwards Lifesciences

First Citizens Bank and Trust Co. bought a new stake in Edwards Lifesciences Corporation (NYSE: EW) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 9,174 shares of the medical research company's stock, valued at approximately $792,000. Other

Assenagon Asset Management S.A. grew its holdings in shares of Edwards Lifesciences Corporation (NYSE: EW) by 50.0% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,719,271 shares of the medical research company's stock after buying an additional 906,345 shares during the

Elutia (NASDAQ: ELUT - Get Free Report) and Edwards Lifesciences (NYSE: EW - Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, risk, valuation, institutional ownership, analyst recommendations and earnings. Analyst Ratings This is a summary of current recommendations

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended Sept. 30, 2026 after the market closes on Wednesday, Nov. 4, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at ir.edwards.com. About Edwards Lifescie.